32 results about "Human leucocyte antigen" patented technology

The invention provides a humanized transformed T cell receptor (TCR) SRm1g13t. The humanized T cell receptor has the characteristic of combining human antigen MAGE-A3:112-120(KVAELVHFL) and human leucocyte antigen (HLA) compound: pHLA(MAGE-A3), wherein the combination affinity of SRm1g13t for the pHLA(MAGE-A3) compound is at least 2 times of that of a corresponding mouse TCR SRm1 for the pHLA(MAGE-A3) compound. The invention further provides a fused molecule of TCR and a therapeutical agent. The TCR can be singly used, and can also be combined with the therapeutical agent for use.

The invention provides a sequencing-based typing method of human leucocyte antigen (HLA)-Cw genes, comprising the following steps: a. carrying out PCR amplification on a typing target region by two pairs of PCR amplification primers, wherein the first pair of amplification primers contains a sequence from a first exon to a fourth exon, and the second pair of amplification primers contains a sequence from a fifth exon to an eighth exon; and b. carrying out sequencing reaction on the obtained amplified product by twelve forward sequencing primers and reverse sequencing primer, wherein the first exon, the second exon, the third exon, the fourth exon and the fifth exon of the HLA-Cw genes are subject to forward and reverse sequencing respectively, the sixth exon is subject to forward sequencing and the seventh exon is subject to reverse sequencing. The invention is established based on full-length sequence of the HLA-Cw genes and single nucleotide polymorphisms (SNPs) data, solving the problems of missed detection of an allele Cw*0706 occurred in population detection via an AlleleSEQR HLA-Cw plus kit and ambiguous results occurred in sequencing-based typing. The method is applicable to high-resolution horizontal gene typing of the HLA-Cw genes in Chinese population, and is beneficial to various application and basic researches of the HLA-Cw genes.

The invention discloses HTNV-NP (Hantaan virus nucleoprotein)-specific CTL (cytotoxic T lymphocyte) epitope peptides and application thereof. The CTL epitope peptides have amino acid sequences shown in SEQ ID NO:1-12. Especially, HLA-I (human leucocyte antigen-I) molecule restricted epitope polypeptide in the HTNV-NP-specific CTL epitope peptides can induce CD8+T lymphocyte to generate strong cellular immune response and secrete high-level IFN-gamma. The HTNV-NP-specific CTL epitope peptides can be used for preparing CTL epitope peptide vaccines or for inducing the generation of CTL epitope peptide-specific CTL, or for preparing CTL epitope peptide-sensitized antigen presenting cells and have bright development and application prospects in the field of specific immunization therapy of HFRS (hemorrhagic fever with renal syndrome).

The invention discloses an HLA (human leucocyte antigen) typing method based on a PacBio RS II sequencing platform. A collected sample is subjected to DNA extraction and then to PCR (polymerase chain reaction) amplification, PCR products are mixed to establish a 10k library, and PacBio RS II sequencing is performed; then, original data obtained by sequencing are corrected, and HLA typing is performed with software programs. Compared with existing HLA typing methods, the HLA typing method has super-high resolution and is of important value to applications such as clinical graft tissue matching, population genetics, anthropology and evolutiology, as well as basic research work.

The invention provides a preparation method for a dendritic cell vaccine loaded by a tumor specific antigenic epitope polypeptide. The method comprises the following steps: adopting a human leucocyte antigen A201 positive epitope of an epithelial cell adhesion molecule identified by tumor specific expression, namely a polypeptide composed of amino acid sequences represented by any one of SEQ ID NO.1-6; loading dendritic cells by using the polypeptide of any one of the SEQ ID NO.1-6 to prepare the dendritic cell vaccine. The dendritic cell vaccine can be used for initiating a very strong target anti-tumor cytotoxic T lymphocyte effect. The invention further provides a kit for preparing the dendritic cell vaccine loaded by the tumor specific antigenic epitope polypeptide.